Clinical Management of Kidney Transplants
description
Transcript of Clinical Management of Kidney Transplants
![Page 1: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/1.jpg)
Clinical Management of Kidney Transplants
Dr. Michael HadjigavrielDirector Nephrology
Larnaca General Hospital Cyprus - 2009
-Overview--Overview-
![Page 2: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/2.jpg)
Pre-transplant Management
Donors/Recipients
![Page 3: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/3.jpg)
Donors/Recipients
• ABO compatibilityA»A, A»ABB»B, B»ABAB»AB O»O, O»A, O»B, O»AB
• Rhesus compatibility not necessary
(Blood group antigens that determine blood type are found on all cells while antigens for the rhesus are present only on the red blood cells)
![Page 4: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/4.jpg)
Donors/Recipients
• Non ABO Compatible Donors– To increase graft availability
some centers started to use non ABO compatible donors after specific treatment with rituximab (chimeric monoclonal antibody against the protein CD20) and plasmapheresis.
– Results are comparable and very promising
![Page 5: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/5.jpg)
Donors/Recipients
• HLA Compatibility
more common HLA antigens between donor and
recipient > better graft survival.
![Page 6: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/6.jpg)
HLA Typing
• Process of identifying genetic markers (antigens) on leucocytes
• 3 general groups of HLA: A, B, DR
• Each group is inherited as part of a set from each parent and it’s known as Haplotype
• There are many HLA proteins: HLA –A 325, HLA-B 592, HLA-DR 451
• 220 genes coding MHC
![Page 7: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/7.jpg)
Example
• Patient x has:
-1 to 4 chances to have identical match with his brothers/sisters
(i.e. to share the same 2 haplotypes)
-1 to 2 chances to have partial compatibility with his brothers/sisters
(i.e. to share 1 haplotype)
-1 to 8 chances of compatibility with his cousins
![Page 8: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/8.jpg)
Donors/Recipients
• Cross match– Positive:
presence of antibodies against donor antigens.
– Negative: No antibodies against donor antigens
In normal practice to proceed to Tx cross match must be NEGATIVE
![Page 9: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/9.jpg)
Donors /Recipients
Kidney Transplantation with“Positive x-match” and “Sensitized patients”
To increase number of transplants in positive x-match and/or sensitized patients (until lately non transplantable) some centers proceed to transplantation after removal of cytotoxic antibodies* from recipients with medications (rituximab, etc) and plasmapheresis (prior and after tx accordingly).
• Results are comparable and very promising(*These antibodies usually occur after pregnancy, blood transfusions or previous transplantations)
![Page 10: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/10.jpg)
Donors/Recipients
Donors Excluded • Age >70 years: Special
criteria applied• Carriers of chronic
infections: HIV, Hep. B, Hep C, etc.: Special criteria applied
• Carriers of chronic diseases: diabetes, cancer, amyloidosis, vascular patients, autoimmune diseases, renal dysfunction, etc.: Special criteria applied
![Page 11: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/11.jpg)
Donors/Recipients
Recipients excluded:• Age >70: Special
criteria applied• High risk patients for major
surgery:severe cardiovascular disease, etc
• High risk patients for: cancer, acute or chronic infections, etc
• Surgical impediments: calcified vessels, bladder diseases (neurogenic, BPH) etc.
![Page 12: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/12.jpg)
Donor / Recipient preparation
![Page 13: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/13.jpg)
Donor Preparation
• General biochemistry• Hematology• Viral studies (HBsAg, HCV, HIV, CMV, EBV, HSV)
Ab’s or DNA accord.• Hormones (PSA, CEA,CA 9-19, CA 125, AFP, etc)• Urine (routine, culture, 24 hour protein, creatinine
clearance)• Imaging (US, IVP, MRA, chest x-ray)• Specialized evaluation (ECG, cardiac echo, stress
test, etc)• Any other test or Specialized evaluation if
indicated.
![Page 14: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/14.jpg)
Recipient preparation
• General biochemistry• Hematology• Viral studies (HBsAg, HCV, HIV, CMV, EBV, HSV)
Ab’s or DNA accordingly.• Hormones (PSA, CEA, AFP,CA 9-19, CA 125, etc)• Imaging (US abdomen,Plain Abdomen & pelvis,
Chest x-ray)• Specialized evaluation (ECG, cardiac echo, stress
test, urodynamics, etc)• Any other test or Specialized evaluation if indicated.
![Page 15: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/15.jpg)
Recipient Preparation
• Pre-transplant immunosuppression:Protocol used:24 hours before Tx: – Steroids (prednisone) 5mg/kg/bw
(in divided doses)– MMF 500-1000 mg BD – 1 hour before Tx:
basiliximab (Simulect) 20mg iv (stat) (To be repeated on day 4 after tx).
• All recipients are started on Gancyclovir and Broad Spectrum Antibiotic Prophylaxis before surgery
![Page 16: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/16.jpg)
Post-transplant Management
Recipients
![Page 17: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/17.jpg)
Recipients
Post-transplant immunosuppression:
Different Protocols in use:
• CyA+MMF+Pred• CyA+SIR+Pred• CyA+EVER+Pred• TAC+MMF+Pred• TAC+SIR+Pred• SIR+MMF+Pred
+ Basiliximab or daclizumab : monoclonal antibodies anti inter leukin – 2 receptor antagonist (IL-2R)
![Page 18: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/18.jpg)
Recipients
Right after TX and or within 24 hrs:
- Solumedrol 125-500 mg BD x 3 days and
Accordingly (Initial Dose):- CyA: ~8mg/kg/bw/day in 2 doses - MMF ~1000-2000 mg/day in 2 doses - TAC ~0.1-0.2/kg/bw/day in 2 doses- EVER ~1.5mg/day in 2 doses- SIR ~5mg/day in 2 doses
![Page 19: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/19.jpg)
Recipients
• Usually 7-10 days after initial dosing, doses of immunosuppressants are adjusted to obtain desired levels.
• Drug serum levels depend on protocol (combination of immunosuppressants) used.
• Special attention to other drugs influencing serum levels of immunosuppressants.
• Drug monitoring should be scheduled and performed periodically together with patient follow up.
![Page 20: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/20.jpg)
Kidney Transplants
Post-transplant complications
Surgical Complications• renal artery thrombosis /
stenosis• venous thrombosis /
stenosis• urinary leak (from UV
anastomosis, ureter) • UV stenosis• lymphoceles
![Page 21: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/21.jpg)
Kidney Transplants
Post-transplant complicationsMedical (pathology) immediate or chronic
Complications• Rejection: Hyperacute/acute/chronic (CAN)• Infection: viral/ bacterial/ mycotic/
opportunistic• Cardiovascular: CAD/ CHF/ CVA/ HT• Cancer: skin/ blood/ solid organs• Diabetes / cataract/ hirsutism/ alopecia/
gum hypertrophy/ obesity/ impotence/ etc• Drug toxicity (calcineurin inhibitors, etc.)
![Page 22: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/22.jpg)
Kidney Transplants
Follow up schedule for Tx patients:
1st month: 3 times a week
1-3months: once a week
3-6months: once every 2 weeks
6 months-2 years: once a month
2 years and over: every 2 months
![Page 23: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/23.jpg)
Follow up schedule should include :
• Haematology• General biochemistry• Urine (MSU, 24 hr collection)• Drug level monitoring• Detailed Clinical examination • Diagnostic imaging
(when necessary)• Tx Biopsy (when necessary)• Special attention to:
cardiovascular disease, neoplastic disease, infection and parathyroid function
![Page 24: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/24.jpg)
Specific and General Information
on Kidney Tx
![Page 25: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/25.jpg)
Specific Information
• Kidneys from LRD:
Less cold ischemia time, less ATN, prompt diuresis, usually no need for HD after TX.
• Kidneys from CAD:
longer cold ischemia time, more ATN, delayed diuresis, more frequent need for HD after TX.
![Page 26: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/26.jpg)
Specific Information
Treatment of Acute rejection:• Steroid boluses: Methylprednisolone • ATG: Polyclonal antibody, Rabbit antihuman
activated T-Lymphocyte globulin.• OKT3: murine monoclonal IgG2a antibody that
specifically reacts with the T cell receptor-CD3 complex on the surface of circulating human T cells.
• ATGAM: lymphocyte immune globulin, anti-thymocyte globulin [equine].
• Rituximab: Chimeric monoclonal antibody against the protein CD20.
• Plasmapheresis• Irradiation of graft (abandoned method in majority of
centers)
![Page 27: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/27.jpg)
Specific Information
CAN ( Chronic Allograft Nephropathy)Etiology: • Cold Ischemia time• Renal injury• Degree of immunosuppression• N° of acute rejections• Drug toxicity• Etc.
![Page 28: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/28.jpg)
Specific Information
CAN (Chronic Allograft nephropathy)Clinical signs and symptoms:• Chronic reduction of renal function: rising creatinine,
reduced GFR, etc.• Biopsy: CAN (lymphomonocytic infiltration, sclerosis,
etc)• US: increased ecogenicity of graft• Other signs and symptoms of progressive CRF
(hypertension, proteinuria, etc).
![Page 29: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/29.jpg)
Specific Information
CAN (Chronic allograft nephropathy)
Treatment:• Change protocol of
immunosuppression (?)• Eliminate worsening
cofactors (nephrotoxic drugs, stabilize hemodynamics, etc.)
• If acute on chronic rejection is suspected treat accordingly.
![Page 30: Clinical Management of Kidney Transplants](https://reader035.fdocuments.net/reader035/viewer/2022062723/56813e60550346895da865fd/html5/thumbnails/30.jpg)
Thanks
Any Questions?